Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 May 2025 | Story Martinette Brits | Photo Kaleidoscope Studios
Prof Hendrik Swart
Prof Hendrik Swart from the UFS Department of Physics was recently recognised by the Golden Key Honour Society Southern Africa as one of South Africa’s 300 most influential leaders.

Prof Hendrik Swart from the University of the Free State (UFS) Department of Physics was recently honoured at the Golden Key Honour Society Southern Africa’s Black Tie Gala Event, held on 23 May 2025. The event celebrated 300 of South Africa’s most influential leaders across academia, industry, government, and the financial sector.

Prof Swart, who is an NRF B1-rated researcher and currently also holds the SARChI Research Chair in Solid-state Luminescent and Advanced Materials (2023-2027), described the recognition as both meaningful and affirming at this stage of his academic journey.

“Being recognised by such a prestigious organisation is a meaningful acknowledgment of my academic efforts and personal dedication,” he says. “It was a moment of validation and inspiration, reminding me that hard work truly pays off.”

While the exact selection criteria were not publicly detailed, the emphasis was placed on academic excellence, scholarship, and leadership.

This is not Prof Swart’s first recognition from the Golden Key Honour Society. In 2012, the UFS student chapter awarded him honorary membership for his contributions as a mentor and supervisor – an early nod to his lasting impact on student success.

“The student chapter here on campus gave me some recognition by awarding me honorary membership,” he recalled. “It meant a lot to me as a mentor.”

The gala itself offered more than accolades – it created a space for meaningful exchange. Prof Swart reflected warmly on reconnecting with one of his former students from the early 2000s, calling it a highlight of the evening.

Looking ahead, Prof Swart welcomed the society’s plans to continue this initiative across the country.

“This was the first time they had an event like this, but more are expected to follow. I see it as a good initiative to mingle with other sectors in South Africa.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept